Next Article in Journal
Clear Cell Myoepithelioma of Palate with Emphasis on Clinical and Histological Differential Diagnosis
Previous Article in Journal
Pellagra: A Non-Eradicated Old Disease
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Clinics and Practice
Volume 4
Issue 1
10.4081/cp.2014.635
clinpract-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Clinics and Practice is published by MDPI from Volume 11 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Acute Acalculous Cholecystitis in a Patient with Metastatic Renal Cell Carcinoma Treated with Sunitinib

by
Leonardo Gomes da Fonseca
*,
Romualdo Barroso-Sousa
,
Jorge Sabbaga
and
Paulo Marcelo Hoff
Division of Medical Oncology, Institute of Cancer of the state of São Paulo, University of São Paulo, Brazil
*
Author to whom correspondence should be addressed.
Clin. Pract. 2014, 4(1), 635; https://doi.org/10.4081/cp.2014.635
Submission received: 7 March 2014 / Revised: 18 April 2014 / Accepted: 18 April 2014 / Published: 30 April 2014

Abstract

A 55-year old man was treated with sunitinib 50 mg/day for 4 weeks on and 2 weeks off, as a first-line therapy for metastatic renal cell carcinoma. During the fourth week of the first cycle, he was admitted to the Emergency Department with abdominal pain and vomiting. Acute acalculous cholecystitis was diagnosed. Sunitnib-associated cholecystitis is a rare adverse event previously reported in few cases. The mechanism behind this complication is not fully understood, although vascular endothelial dysfunction may play a role. The use of this drug is expanding in clinical oncology, and physicians should be aware of this life-threating adverse event.
Keywords: acalculous cholecystitis; sunitinib malate; angiogenic agents; receptor tyrosine kinase acalculous cholecystitis; sunitinib malate; angiogenic agents; receptor tyrosine kinase

Share and Cite

MDPI and ACS Style

Gomes da Fonseca, L.; Barroso-Sousa, R.; Sabbaga, J.; Hoff, P.M. Acute Acalculous Cholecystitis in a Patient with Metastatic Renal Cell Carcinoma Treated with Sunitinib. Clin. Pract. 2014, 4, 635. https://doi.org/10.4081/cp.2014.635

AMA Style

Gomes da Fonseca L, Barroso-Sousa R, Sabbaga J, Hoff PM. Acute Acalculous Cholecystitis in a Patient with Metastatic Renal Cell Carcinoma Treated with Sunitinib. Clinics and Practice. 2014; 4(1):635. https://doi.org/10.4081/cp.2014.635

Chicago/Turabian Style

Gomes da Fonseca, Leonardo, Romualdo Barroso-Sousa, Jorge Sabbaga, and Paulo Marcelo Hoff. 2014. "Acute Acalculous Cholecystitis in a Patient with Metastatic Renal Cell Carcinoma Treated with Sunitinib" Clinics and Practice 4, no. 1: 635. https://doi.org/10.4081/cp.2014.635

Article Metrics

Back to TopTop